Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...

Restoring the gut microbiota through fecal microbiota transplantation reversed these effects. The treatment replenished CX3CR1-positive NK cells, reduced lung damage, and improved survival. Targeted ...

Since scientists first discovered that human immune cells could be modified to become cancer-fighting agents, they've been trying to engineer a cell that's effective against solid tumors, which ...

Researchers at the Ribeirao Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 ...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 ...

Irish and American researchers have identified a potential new way to counter treatment‑resistant prostate cancer by ...

About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

Scientists in Brazil are refining the design of CAR-engineered immune cells to make them more precise and powerful against cancer.

Since scientists first discovered that human immune cells could be modified to become cancer-fighting agents, they've been trying to engineer a cell ...

Sepsis and severe pneumonia are frequently accompanied by disruption of the gut microbiota, leading to immune dysfunction and ...

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...